Medindia

X

Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference

Thursday, July 22, 2010 AIDS/HIV News J E 4
Advertisement
Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 Study

Inquiries:

UK Media inquiries:

Rebecca Hunt

Claire Brough

(020) 8380 6275

(020) 8047 5502

US Media inquiries:

Marc Meachem

(919) 483 5005

GSK European Analyst/Investor inquiries:

David Mawdsley

(020) 8047 5564

Sally Ferguson

(020) 8047 5543

Gary Davies

(020) 8047 5503

GSK US Analyst/ Investor inquiries:

Tom Curry

(215) 751 5419

Jen Hill Baxter

(215) 751 7002

Shionogi & Co., Ltd. Enquiries

Corporate Communications

+81 6 6209 7885

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
TMC278 Pivotal Phase 3 Clinical Trials Achieve Pri...
S
Medifast to Participate in the 13th Annual Canacco...